Tatsunori Shimoi, Head of Physician at National Cancer Center Hospital, Japan, shared a post on X:
“ASCO 2026 Breast Cancer (Metastatic)
Rapid Oral session May 31, 11:30-13:00PM
- ASCENT-04 biomarker subgroup analysis
- ASCENT-03 biomarker subgroup analysis
- Does access to food and poverty impact genomic abnormalities in MBC?
- evERA (giredestrant + everolimus) post-PD treatment
- Effectiveness of continuing CDK4/6 inhibitors post-PD in PALMARES-2 (Italian RWD)
- Final OS results from the PATHWAY trial!
- AMBITION (JCOG1919E) PTX+BEV±Atezolizumab
- ADC efficacy in subsequent treatment when Bevacizumab is used
- DB09 (T-DXd+Per) long-term treatment outcomes by response.”
